中文摘要：

目的观察伊立替康联合雷替曲塞方案治疗晚期结直肠癌的有效性和安全性。方法收集28例一线化疗方案治疗失败或缓解后再进展的晚期结直肠腺癌患者,行伊立替康联合雷替曲塞化疗,方案：伊立替康150~180mg/m2,静脉滴注,第一天;雷替曲塞3mg/m2静脉滴注,第一天;21d为1个周期,21d后再重复给药,每2~3个周期后评价疗效,治疗期间评估不良反应。结果所有患者均可评价疗效,其中PR 2例,SD19例,PD 7例,无CR者,ORR为7.14%,DCR为75%。中位PFS 6个月,中位OS不小于11.5个月。最常见的毒副反应是中性粒细胞减少和腹泻。结论雷替曲塞联合伊立替康方案有效率高,毒副反应小,可以作为晚期结直肠癌的二线治疗方案。

英文摘要：

Objective To observe the efficacy and toxicity of irinotecan plus raltitrexed as second-line chemotherapy for advanced colorectal cancer. Methods Twenty-eight patients with advanced colorectal cancer who failed to first-line chemotherapy.The doses of drugs were as follows,CPT-11 150-180mg/m2 ivgtt on day 1 and raltitrexed 3mg/m2 on day 1.One cycle lasted 21 days.After every two or three cycles,therapeutic efficacy was evaluated.The efficacy,side effects,and safety of the treatment were observed. Results All patients successfully completed the the treatment plan. There was 0 case of complete recovery, 2 partial recovery, 19 stable disease,and 7 progressive disease.The overall response rate was 7.14%,the disease control rate was 75%.The mean progression free survival was 6 months,and the mean overall survival was no less than 11.5 months.The most common side effects were neutropenia and diarrhea. Conclusion Irinotecan plus raltitrexed as second-line chemotherapy for advanced colorectal cancer has a high efficacy with acceptable tolerability,and is a therapy worth considering for advanced colorectal cancer.